Want to join the conversation?
$AMGN said it launched 6 new products last year, 2 in the cardiovascular arena and 4 in cancer. The company stated these products are still in the early stages of their launch cycle globally. $AMGN remains excited about the long-term prospects of Repatha and looks forward to important clinical data set to emerge later in 2016 and early 2017.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?